Savolitinib

Manufactured by MedChemExpress

Sourced in United States, Jersey

Savolitinib is a potent and selective inhibitor of the mesenchymal-epithelial transition (MET) receptor tyrosine kinase. It is designed to block the activity of the MET receptor, which is involved in various cellular processes such as cell growth, survival, and migration.

Automatically generated - may contain errors

Lab products found in correlation

Cabozantinib, by Selleck Chemicals (1 mentions) Tepotinib, by Selleck Chemicals (1 mentions) Dasatinib, by Selleck Chemicals (1 mentions) Crizotinib, by Selleck Chemicals (1 mentions) Azd1208, by Selleck Chemicals (1 mentions) Dimethyl sulfoxide (dmso), by Merck Group (1 mentions)

2 protocols using savolitinib

Evaluation of Kinase Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tepotinib, AZD1208 and dasatinib were purchased from Selleck Chemicals (Houston, TX, U.S.). Savolitinib was purchased from Med Chem Express (Monmouth Junction, NJ, U.S.). PIM447 (LGH447), crizotinib and cabozantinib were purchased from Selleck Chemicals (Houston, TX, U.S.). Drugs were prepared in dimethyl sulfoxide (DMSO) at a concentration of 10–100 mM stock solutions and stored at −20 °C. Further dilutions were made in culture medium to final concentration before use. Primary antibodies and secondary antibodies used are in Table S1.

Attili I., Bonanno L., Karachaliou N., Bracht J.W., Berenguer J., Codony-Servat C., Codony-Servat J., Aldeguer E., Gimenez-Capitan A., Dal Maso A., Fassan M., Chaib I., Molina-Vila M.A., Passaro A., de Marinis F., Pasello G., Guarneri V., Conte P.F, & Rosell R. (2020). SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. Translational Lung Cancer Research, 9(5), 1810-1821.

+ Open protocol

+ Expand

Evaluation of Eight MET-TKIs

Check if the same lab product or an alternative is used in the 5 most similar protocols

Eight MET-TKIs (type Ia, crizotinib; Ib, capmatinib, tepotinib, and Savolitinib; type II, cabozantinib, glesatinib, and merestinib; type III, tivantinib) were evaluated in this study. Savolitinib was purchased from MedChem Express (Monmouth Junction, New Jersey). All other drugs were purchased from Selleck Chemical (Houston, Texas). These drugs were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and stored at -20 C until use.

Fujino T., Kobayashi Y., Suda K., Koga T., Nishino M., Ohara S., Chiba M., Shimoji M., Tomizawa K., Takemoto T, & Mitsudomi T. (2019). Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 14(10).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!